AEGR may take a hit momentarily, but not from any smart money, only from retail investors day-trading to see if they can make it move. Anybody with any understanding of the market will know that Kynamro's approval will turn to a good thing for AEGR. Only those behind the power curve, and didn't know that lomitapide was approved back on December 24, would try to knock AEGR on this. AEGR was approved first, will be first to market, and will dominate marketshare right out of the gate.
The REMS on Kynamro is rightfully restrictive, but the bigger issue is the difference between FDA approval and commercial success. I think a long time ago they had a treatment for AIDS, but the market never bought it, so the FDA approval became irrelevant. Such will be the case here.